3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Available
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
181
Observational
2
Expanded_access
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Plasma cell
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Primary Myelofibrosis
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Amyloidosis
1
Interventions
nilotinib
5
dabrafenib
4
Nivolumab
4
Afatinib
4
trametinib
3
regorafenib
3
midostaurin
3
elotuzumab
3
TIC10 compound
3
Sunitinib
3
Prednisone
3
Capecitabine
3
Abiraterone Acetate
3
3-Iodobenzylguanidine
3
venetoclax
2
tucatinib
2
tempol
2
tazemetostat
2
talquetamab
2
talimogene laherparepvec
2
ruxolitinib
2
pomalidomide
2
olaparib
2
niraparib
2
leronlimab
2
lenvatinib
2
ibrutinib
2
gilteritinib
2
ceritinib
2
brexucabtagene autoleucel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Expanded_access
×
venetoclax
×
Clear all
NCT03123029
2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT03592576
2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available